Pleiotropic Pathway Modifier Compounds for Multi-Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for regulating protein expression in tumor cells, immune cells, and other disease-related cells are limited in their ability to induce degradation of multiple proteins involved in carcinogenesis and immunity.
Innovation Solution
Development of pleiotropic pathway modifier (PPM) compounds that act as multifunctional molecular glues, binding to cereblon (CRBN) and histone deacetylases (HDACs), to induce degradation of proteins implicated in carcinogenesis and immunity, while also inhibiting the enzymatic activities of HDACs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional targeted protein degradation strategies (PROTACs) are used, then protein degradation capability is improved, but molecular size and complexity increase
Solution Approach 1:
The patent extracts and eliminates the VHL-binding component from the PROTAC structure, retaining only the CRBN-binding warhead and linker. This extraction reduces molecular weight while preserving the essential protein degradation function through CRBN-mediated ubiquitination of target proteins.
Solution Approach 2:
The patent creates a universal CRBN-binding platform that can degrade multiple different target proteins (c-MYC, HDAC, IRF4, IKZF1, IKZF2, IKZF3) through a single molecular glue mechanism, replacing the need for multiple separate PROTAC compounds with one multifunctional agent.
2Productivity
If molecular glues are used for protein degradation, then degradation efficiency is improved, but bioavailability may be compromised due to larger molecular size
Solution Approach 1:
The patent removes the VHL-interacting portion from the molecular glue structure, leaving a streamlined CRBN-target protein binder. This extraction reduces molecular size to improve bioavailability while maintaining degradation efficiency through CRBN-mediated proteolysis.
Solution Approach 2:
The patent optimizes molecular parameters by reducing molecular weight and complexity while maintaining the essential CRBN binding affinity and target protein recruitment capability. This parameter optimization balances degradation efficiency with pharmacokinetic properties for improved bioavailability.
3Adaptability or versatility
If multiple protein targets are addressed simultaneously, then therapeutic versatility is improved, but compound complexity increases
Solution Approach 1:
The patent designs a universal CRBN-binding molecular glue that simultaneously recruits multiple different target proteins (c-MYC, HDAC, IRF4, IKZF1, IKZF2, IKZF3) for degradation through a single compound structure, achieving multi-target capability without proportionally increasing complexity.
Solution Approach 2:
The patent segments the molecular glue into distinct functional modules: a CRBN-binding warhead, a flexible linker, and target protein-binding moieties. This segmentation allows the compound to interact with multiple targets through modular interactions while maintaining overall structural manageability.
4Reliability
If HDAC enzymatic activity is inhibited, then oncogene expression is reduced, but additional mechanism complexity is introduced
Solution Approach 1:
The patent merges two mechanisms of action into a single compound: (1) molecular glue-mediated protein degradation through CRBN recruitment, and (2) direct HDAC enzymatic inhibition. This combining achieves dual functionality where the same compound simultaneously degrades HDAC protein and inhibits its enzymatic activity, improving oncogene regulation reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PPM compounds effectively induce degradation of target proteins such as c-MYC, HDAC, IRF4, and Ikaros Zinc Finger Transcription Factors, thereby regulating oncogene expression and modulating cytokine production, offering a potential therapeutic approach for various diseases.
Implementation Method 1
One of the major pathways to regulate proteins post-translationally is ubiquitin-dependent proteolysis. The first step in selective degradation is the ligation of one or more ubiquitin molecules to a protein substrate. Ubiquitination occurs through the activity of ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin-protein ligases (E3), which act sequentially to catalyze the attachment of ubiquitin to lysine residues of substrate proteins.
Implementation Method 2
molecular glues are monovalent small molecules that induce protein-protein interactions leading to targeted protein degradation. In contrast, molecular glues are much smaller thus more easily abide by Lipinski's rule of five for drug conformity, which suggests upper limit of molecular properties expected to enhance the probability for good oral bioavailability.
Implementation Method 3
PPM compounds not only induce degradation of proteins implicated in carcinogenesis and immunity, such as c-MYC, HDAC, IRF4, and Ikaros Zinc Finger Transcription Factors (IKZFs), but also directly inhibit the enzymatic activities of HDACs, thereby regulating expression of oncogenes in cells.
Data Source
AI summary
This patent document reveals a class of pleiotropic pathway modifier (known as PPM) compounds that facilitate the degradation of multiple targeted proteins and regulate various signaling events involved in cancer cell survival and proliferation, as well as immune response. These compounds effectively recruit disease-causing proteins for swift destruction through the ubiquitin-proteasome pathway, exhibiting potent anti-cancer, immunomodulatory, and anti-inflammatory properties. Additionally, disclosed herein are methods for treating diseases encompassing cancers, autoimmune disorders, infections, inflammations, and other ailments.